I certainly believe you're right about news before March
I certainly believe you're right about news before March unless the size of the trial has expanded very dramatically, and OWCP management has a reason that they cannot officially tell us that.
It's my belief that all along they could have updated the clinical trials database, but they've made the choice not to do so using the fact that the trial is being run in Israel.
I believe if they had updated the trial it would have become a Phase 1/2 where the Phase 1 would have been pure safety on healthy patients, and the Phase 2 would have been efficacy on patients with a variety of skin diseases.
We have all seen posters say this is essentially what they heard from people with ties to the company, but that doesn't make it official. Had they updated the clinical trials site, it would have become official, even if they issued nothing else.
The real problem with understanding the trial is knowing it's size. Originally the trial was to be done with 20 healthy patients. We don't know if the expansion of the trial was for 5 patients each with 3 different skin diseases, or 25 patients each for perhaps 5 different skin diseases. The smaller figures are certainly low enough that recruitment could have been concluded in a couple months, and the trial nearly concluded. The larger numbers could easily suggest the trial is still recruiting, and could be for at least a few more months, and then they observe each patient for 60 days, so the trial won't be unblinded until 60 days after the last patient is enrolled in the trial.
If the company were willing to give us some big, and very important news, all they'd need to do is clarify what's being done in the expansion of the trial. It's the total lack of information that keeps the stock price down, they don't need to tell us all that's happening, but a little guidance that's official about what they're doing would provide a lot of support for the stock price.
Gary
1
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...
Continue Reading
Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...
Continue Reading
They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...
Continue Reading
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...
Continue Reading
The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...
Continue Reading
Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...
Continue Reading
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...
Continue Reading
Top 5 Most Recently Viewed Articles
Exciting Updates from Verint's Investor Day Event Verint® (Nasdaq: VRNT), known as The CX Automation Company™, has recently held its much-anticipated Investor Day, highlighting significant advancements and outlined strategies aimed at shaping the future of customer experience (CX). The event kicked off with CEO Dan Bodner expressing enthusiasm about discussing the...
Continue Reading
Tri Pointe Homes Reports Outstanding Third Quarter Performance Tri Pointe Homes, Inc. (NYSE: TPH), a leading homebuilder in America, has unveiled strong results for the third quarter of 2025, highlighting significant achievements in home deliveries and financial performance. Key Highlights of Q3 2025 The company has reported a total of 1,217 new home deliveries during...
Continue Reading
Main Street Capital Reports Impressive Financial Results Main Street Capital Corporation (NYSE: MAIN) is excited to share its financial results for the third quarter of 2024. With solid performance reflected in higher net investment income and a robust capital position, the company demonstrates its commitment to delivering value to shareholders. Highlights from Q3 2024...
Continue Reading
Key Disclosure of Rathbones Group Plc In the financial landscape, transparency is of utmost importance, especially when significant interests in securities come to light. Rathbones Group Plc has provided a crucial disclosure as they maintain an interest in relevant securities of Warpaint London Plc, representing over 1% of their shares. This type of disclosure aligns with...
Continue Reading
Overview of the Electric Trucks Market Growth The global electric trucks market is projected to witness significant growth, with estimates indicating an increase of USD 20.32 billion from recent years through to 2028. This growth trajectory shows an impressive compound annual growth rate (CAGR) of approximately 35.44%. The rising demand for fuel-efficient and low-emission...
Continue Reading
